发明名称 Benzhydryl derivatives
摘要 Compounds having a benzhydryl structure represented by formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratory tract.
申请公布号 US9145409(B2) 申请公布日期 2015.09.29
申请号 US201414560009 申请日期 2014.12.04
申请人 CHIESI FARMACEUTICI S.p.A 发明人 Amari Gabriele;Armani Elisabetta;Capaldi Carmelida;De Fanti Renato;Riccaboni Mauro;Baker-Glenn Charles;Van De Poël Hervé
分类号 C07D453/02;A61K31/444;A61K31/4545;A61K31/496 主分类号 C07D453/02
代理机构 Oblon, McClelland, Maier & Neustadt, L.L.P. 代理人 Oblon, McClelland, Maier & Neustadt, L.L.P.
主权项 1. A compound of formula (I):wherein each R1 is independently hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, hydroxy, —SO2NR6R7, —CN, —NR8SO2R9, —NR6R7, —CONR6R7, or —NR8COR9, wherein said (C1-C4) alkyl is optionally substituted by one or more groups selected from the group consisting of (C3-C7) cycloalkyl, hydroxyl, and —NR6R7 and wherein said (C1-C4) alkoxy is optionally substituted by one or more halogen atoms or (C3-C7) cycloalkyl groups, wherein, R6 is hydrogen or (C1-C6) alkyl;R7 is hydrogen or (C1-C6) alkyl;R8 is hydrogen or (C1-C6) alkyl;R9 is hydrogen or (C1-C6) alkyl; n is an integer ranging from 1 to 3; each R2 is independently hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4)haloalkyl, hydroxy, —SO2NR10R11, —CN, or —NR12SO2R13, wherein said (C1-C4) alkyl and said (C1-C4) alkoxy are optionally substituted by one (C3-C7) cycloalkyl groups, wherein R10 is hydrogen or (C1-C6) alkyl;R11 is hydrogen or (C1-C6) alkyl;R12 is hydrogen or (C1-C6) alkyl;R13 is hydrogen or (C1-C6) alkyl; m is an integer ranging from 1 to 3; R3 and R4 are different or the same and are independently: H;—(C3-C7) cycloalkylcarbonyl;(C1-C6) alkyl, optionally substituted by one or more substituents selected from the group consisting of (C3-C7) cycloalkyl and (C5-C7) cycloalkenyl;(C1-C6) haloalkyl;(C3-C7) cycloalkyl;(C5-C7) cycloalkenyl;(C2-C6) alkenyl; and(C2-C6) alkynyl; or R3 and R4, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (r) fused to the phenyl moiety which bears groups —OR3 and —OR4, wherein asterisks indicate carbon atoms shared with such phenyl ring: each R5 is independently CN, NO2, CF3, or halogen; k is 0 or an integer ranging from 1 to 3; L1 is selected from the group consisting of: a bond,—(CH2)p-,[3]-(CH2)p—O-[4][3]-(CH2)p—NR10—(CH2)t-[4][3]-(CH2)p—OC(O)-[4][3]-(CH2)p—NR10C(O)-[4][3]-(CH2)p—NR10S(O2)-[4], and[3]-(CH2)p—S(O2)—N(R10)-[4]wherein [3] and [4] represent, respectively, the point of attachment of group L1 to the carbonyl group and to the ring W and whereinR10 is as described above,p is an integer ranging from 1 to 4 andt is an integer ranging from 1 to 4 W is a divalent group selected from the group consisting of arylene, (C5-C6)-heteroarylene, and saturated monocyclic (C3-C7)-heterocycloalkylene; L2 is a bond, —C(O)—, —S—, —S(O)—, —S(O)2—, or —(CH2)q— wherein q is 1 or 2; L3 is absent or is ortho-, meta-, or para-phenylene, or bivalent (C5-C6)-heteroarylene L4 is —(CH2)r-, [1]—(CH2)r—O-[2], [1]-OC(O)-[2], or [1]-C(O)O-[2] wherein r is 1 or 2 and [1] and [2] represent respectively the point of attachment of group L4 to the group L2 (or L3 when present) and to the phenyl ring; Z is NH, CH2 or O; and A is a nitrogen containing group which is: a group (a) which is —(CH2)s—NR16R17 wherein s is an integer ranging from 1 to 4 and R16 and R17 are independently hydrogen or (C1-C4) alkyl; and a group (b) which is a saturated monocyclic, bicyclic or tricyclic heterocyclic ring system optionally substituted by one or two groups R18 which are at each occurrence independently (C1-C4) alkyl or benzyl, an N-oxide on the pyridine ring, or a pharmaceutically acceptable salt thereof.
地址 Parma IT